Ivonescimab, docetaxel

Phase 3Small molecule

Ivonescimab, docetaxel is one of 78 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerNot yet recruiting

Pancreatic CancerRecruiting

Non-Small Cell Lung CancerPhase 3

Not yet recruiting

Pancreatic CancerPhase 3

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Avastin

Verzenio

6 3

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 4

Ivonescimab, docetaxel

AAkeso

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Pancreatic Cancer

NCT06953999

Q2 2030

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT06928389

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

Recruiting·AAkeso·Phase 3·NCT06953999·999 enrolled

Non-Small Cell Lung Cancer1 trial

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Not yet recruiting·AAkeso·Phase 3·NCT06928389·536 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ivonescimab, docetaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ivonescimab, docetaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ivonescimab, docetaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akeso company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAkeso

Ivonescimab, docetaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2030

Trials by Indication[1]

Pancreatic Cancer1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News